BUZZ-Australia's Invex Therapeutics falls as agreement talks fade

Reuters

Sep 30, 2025

BUZZ-Australia's <a href="https://laohu8.com/S/IXC.AU">Invex Therapeutics</a> falls as agreement talks fade

** Shares of Invex Therapeutics IXC.AX fall as much as 3.1% to A$0.155, their biggest intraday pct drop since September 18

** The pharma co says that negotiations with a rare neurological disease therapeutics development firm have been discontinued

** Agreement in regards to complementary neurological treatment asset

** Talks halted due to instability and uncertainty caused after co received notice to remove two of three directors

** YTD, shares up 134.9%

(Reporting by Nichiket Sunil in Bengaluru)

((Nichiket.Sunil@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571360044"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571360044\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571360044?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 09:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571360044","market":"us","top_or_hot":-1,"title":"BUZZ-Australia's Invex Therapeutics falls as agreement talks fade","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/IXC.AU\">Invex Therapeutics</a> falls as agreement talks fade</title></head><body><p>** Shares of Invex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>  <span>IXC.AX</span> fall as much as 3.1% to A$0.155, their biggest intraday pct drop since September 18</p><p>** The pharma co <span>says</span> that negotiations with a rare neurological disease therapeutics development firm have been discontinued </p><p>** Agreement in regards to complementary neurological treatment asset</p><p>** Talks halted due to instability and uncertainty caused after co received notice to remove two of three directors</p><p>** YTD, shares up 134.9%</p><p> (Reporting by Nichiket Sunil in Bengaluru)</p><p> ((Nichiket.Sunil@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Invex Therapeutics falls as agreement talks fade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Invex Therapeutics falls as agreement talks fade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 09:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/IXC.AU\">Invex Therapeutics</a> falls as agreement talks fade</title></head><body><p>** Shares of Invex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>  <span>IXC.AX</span> fall as much as 3.1% to A$0.155, their biggest intraday pct drop since September 18</p><p>** The pharma co <span>says</span> that negotiations with a rare neurological disease therapeutics development firm have been discontinued </p><p>** Agreement in regards to complementary neurological treatment asset</p><p>** Talks halted due to instability and uncertainty caused after co received notice to remove two of three directors</p><p>** YTD, shares up 134.9%</p><p> (Reporting by Nichiket Sunil in Bengaluru)</p><p> ((Nichiket.Sunil@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IXC.AU","symbol_name":"INVEX THERAPEUTICS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH03D:1","article_id":"2571360044","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571360044","pubTimestamp":1759194914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Invex Therapeutics falls as agreement talks fade** Shares of Invex Therapeutics  IXC.AX fall as much as 3.1% to A$0.155, their biggest intraday pct drop since September 18** The pharma co says that negotiations with a rare neurological disease therapeutics development firm have been discontinued ** Agreement in regards to complementary neurological treatment asset** Talks halted due to instability and uncertainty caused after co received notice to remove two of three directors** YTD, shares up 134.9%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IXC.AU":"INVEX THERAPEUTICS LTD","BK7096":"制药"},"translate_title":"随着协议谈判的消退，澳大利亚Invex Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXC.AU":0.9},"content_text":"BUZZ-Australia's Invex Therapeutics falls as agreement talks fade** Shares of Invex Therapeutics IXC.AX fall as much as 3.1% to A$0.155, their biggest intraday pct drop since September 18** The pharma co says that negotiations with a rare neurological disease therapeutics development firm have been discontinued ** Agreement in regards to complementary neurological treatment asset** Talks halted due to instability and uncertainty caused after co received notice to remove two of three directors** YTD, shares up 134.9% (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}